https://www.selleckchem.com/pr....oducts/Trichostatin-
24.0 months, p = 0.01, HR 1.43, 95% CI 1.1-1.9). Median PFS was significantly reduced in the severely co-morbid subgroup (CCI 0-2 9.4 months vs. CCI 3-4 9.6 months vs. CCI ≥5 7.1 months, p = 0.025, HR 1.3, 95% CI 1.0-1.6). This study demonstrated that first line therapy in the TNE NDMM setting resulted in the longest TFI which was modest at a median of 6.9 months, and decreased significantly following subsequent lines of therapy and across the different subgroups by age and by co-morbidities. Therapy objective should be to maximi
Like
Comment
Share
